School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, USA.
Endocrinology. 2022 Dec 19;164(2). doi: 10.1210/endocr/bqac209.
The discovery of hypothalamic hormones propelled exciting advances in pharmacotherapy and improved life quality worldwide. Growth hormone-releasing hormone (GHRH) is a crucial element in homeostasis maintenance, and regulates the release of growth hormone from the anterior pituitary gland. Accumulating evidence suggests that this neuropeptide can also promote malignancies, as well as inflammation. Our review is focused on the role of that 44 - amino acid peptide (GHRH) and its antagonists in inflammation and vascular function, summarizing recent findings in the corresponding field. Preclinical studies demonstrate the protective role of GHRH antagonists against endothelial barrier dysfunction, suggesting that the development of those peptides may lead to new therapies against pathologies related to vascular remodeling (eg, sepsis, acute respiratory distress syndrome). Targeted therapies for those diseases do not exist.
下丘脑激素的发现推动了药物治疗的令人兴奋的进展,并提高了全球的生活质量。生长激素释放激素(GHRH)是维持体内平衡的关键因素,它调节生长激素从垂体前叶的释放。越来越多的证据表明,这种神经肽也可以促进恶性肿瘤和炎症。我们的综述集中在这种 44 个氨基酸肽(GHRH)及其拮抗剂在炎症和血管功能中的作用,总结了该领域的最新发现。临床前研究表明,GHRH 拮抗剂对内皮屏障功能障碍具有保护作用,这表明这些肽的开发可能导致针对与血管重塑相关的病理学(例如,败血症、急性呼吸窘迫综合征)的新疗法。针对这些疾病的靶向治疗尚不存在。